Get the Daily Brief
Latest Biotech News
Live embryo imaging flags mitotic errors — PGT‑A under scrutiny
Researchers using optimized long‑term light‑sheet imaging of human preimplantation embryos observed de novo mitotic chromosome segregation errors at blastocyst stages, findings reported in Nature...
Retrons repurposed — new retron‑based editors promise large DNA fixes
A Nature Biotechnology report and accompanying analyses describe the discovery and engineering of bacterial retrons for precise genome editing. Authors used metagenomic screening to identify...
Biogen bets on C5aR1: $70M upfront for Vanqua’s preclinical asset
Biogen acquired exclusive global rights to Vanqua Bio’s preclinical C5aR1 antagonist (VQ‑201), paying $70 million upfront with additional contingent milestones. The deal reflects Biogen’s renewed...
Ventyx NLRP3 pill slashes inflammation markers — markets rally
Ventyx Biosciences reported Phase II data showing its oral NLRP3 inhibitor VTX‑3232 produced rapid, large reductions in inflammatory biomarkers and liver inflammation measures in patients with...
Regeneron shelves 2seventy CAR‑T — early lymphoma candidate discontinued
Regeneron confirmed it has halted development of a CAR‑T candidate (bbT369) acquired from 2seventy bio and will not proceed to a planned Phase II study. The company described the decision as...
Takeda-Innovent deal: $11.4bn package, $1.2bn up front
Takeda agreed to a multi-asset oncology partnership with China’s Innovent Biologics that includes $1.2 billion in up-front consideration and up to $10.2 billion in milestone payments. The...
Moderna halts CMV shot: Phase III failure forces pullback
Moderna announced that its cytomegalovirus (CMV) mRNA vaccine mRNA‑1647 failed to meet the primary efficacy endpoint in a pivotal Phase III trial and is halting most development of the program....
Regeneron shelves 2seventy CAR‑T bbT369: early program stopped
Regeneron confirmed it has discontinued development of bbT369, a CAR‑T candidate acquired from 2seventy bio, and will not advance the asset into Phase II. The firm described the decision as a...
Ventyx’s NLRP3 inhibitor: single‑arm signal shakes up cardio inflammation space
Ventyx Biosciences reported Phase II results showing its oral NLRP3 inhibitor VTX‑3232 produced rapid reductions in inflammatory biomarkers and surrogate measures of cardiovascular risk, including...
Inhibrx posts phase II win in rare bone cancer — FDA path planned
Inhibrx reported a positive Phase II readout for ozekibart in a rare bone cancer with no approved therapies, prompting the company to plan an FDA submission in the second half of 2026. The...
FDA clears Blenrep comeback — approval split by regimen
The FDA approved GSK’s antibody‑drug conjugate Blenrep for a restricted multiple myeloma indication after a three‑year market withdrawal, authorizing its use in combination with a Velcade‑based...
LNP blueprints: biophysics study links shape to delivery
Two complementary reports mapped lipid nanoparticle (LNP) architectures and linked particle morphology to delivery performance, providing actionable guidance for RNA‑therapeutic formulation....
Retrons retooled: new genome‑editing tool boosts precise insertions
A Nature Biotechnology study and accompanying reports described the discovery and engineering of bacterial retrons as a scalable route to produce multicopy single‑stranded DNA templates inside...
10x, Roche, Prognosys sue Illumina — patents hit spatial, single‑cell tech
10x Genomics joined Roche Sequencing Solutions and Prognosys Biosciences to file two federal lawsuits accusing Illumina of infringing nine patents tied to spatial biology and single‑cell...
Alector’s dementia drug fails Phase III: company halves staff and slumps
Alector reported a negative Phase III readout for its dementia candidate latozinemab, partnered with GSK, prompting a sharp stock drop and plans to cut roughly half of its workforce. The study...
Takeda, Innovent ink $11.4bn I‑O, ADC pact — $1.2bn up front
Takeda and China’s Innovent struck a sweeping oncology collaboration that could reshape both companies’ cancer pipelines. Takeda agreed to jointly develop and commercialize up to three...
Moderna CMV miss: pivotal Phase III fails — program largely halted
Moderna reported that its mRNA‑1647 cytomegalovirus (CMV) vaccine missed the primary efficacy endpoint in a large Phase III trial and will stop most development of the program. The company said...
FDA clears Blenrep return — mixed authorization for multiple myeloma
The FDA granted a constrained approval for GSK’s BCMA‑targeting ADC Blenrep, allowing its use in patients with relapsed or refractory multiple myeloma after at least two prior lines of therapy and...
Deep learning accelerates antibiotic discovery — two Nature Biotech reports
A pair of Nature Biotechnology papers demonstrate that deep‑learning models trained on high‑throughput phenotypic and screening datasets can identify novel antibacterial scaffolds. One study...
Live embryo imaging finds late mitotic errors — PGT‑A accuracy questioned
UK researchers using light‑sheet microscopy published long‑duration live imaging of late‑stage human preimplantation embryos and observed de novo chromosome segregation errors in trophectoderm...